ALNYLAM PHARMACEUTICALS, INC.

Pioneering RNAi gene-silencing therapies for rare genetic and cardiometabolic diseases.

ALNY | US

Overview

Corporate Details

ISIN(s):: US72703U1025 (+1 more)
LEI:
Country:: United States of America
Address:: 675 WEST KENDALL STREET, 2142 CAMBRIDGE
Website:: https://www.alnylam.com/
Sector:: Manufacturing
Industry:: Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

Alnylam Pharmaceuticals, Inc. is a biopharmaceutical company pioneering the development and commercialization of RNA interference (RNAi) therapeutics. This novel class of medicines utilizes a natural biological process to silence specific genes, thereby preventing the production of proteins that cause or contribute to human disease. The company's portfolio of approved medicines targets a range of rare genetic, cardiometabolic, and hepatic infectious diseases, with key products including ONPATTRO®, AMVUTTRA®, GIVLAARI®, and OXLUMO®. Alnylam continues to advance a robust clinical pipeline to address diseases with high unmet medical need, solidifying its leadership in translating RNAi science into transformative treatments for patients globally.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.

Quick Filters:

Filters

Filing Type

Language

Start date

End date

Clear

Bulk Actions:

	Date	Filing	Language	Size	Actions
No filings match the current criteria.

Automate Your Workflow. Get a real-time feed of all ALNYLAM PHARMACEUTICALS, INC. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for ALNYLAM PHARMACEUTICALS, INC.

This data is available as part of our premium data solutions. Contact our team for access.

Request This Data

Need More History? Access decades of standardized financials for ALNYLAM PHARMACEUTICALS, INC. via our API.

Get Historical Data →

Insider Transactions

Date	Insider Name	Position	Type	Shares	Value
No insider transactions recorded for this company.

Peer Companies

Company	Country	Ticker
Mirum Pharmaceuticals, Inc. Develops and commercializes therapies for rare, debilitating liver diseases in children and adults.	United States of America	MIRM
Mithra Pharmaceuticals S.A. Biotech firm developing pharma for women's health: contraception, fertility, and menopause.	Belgium	MITRA
MIZUHO MEDY CO.,LTD. Develops rapid diagnostic tests & gene analyzers for clinical, research & agricultural markets.	Japan	4595
MOA Life Plus Co. Ltd. Develops immunotherapies & consumer solutions for immunity, skin rejuvenation, and pet care.	South Korea	142760
Moberg Pharma Develops & commercializes a leading topical treatment for nail fungus for European markets.	Sweden	MOB
Mochida Pharmaceutical Co.,Ltd. An R&D-driven company making drugs, skincare, and medical equipment for specialized fields.	Japan	4534
Moderna, Inc. Pioneering mRNA science to create transformative medicines and vaccines for diverse diseases.	United States of America	MRNA
MOLECULAR PARTNERS AG Biopharma firm developing novel DARPin® protein therapies for cancer and serious diseases.	United States of America	MOLN
Monopar Therapeutics Clinical-stage biotech developing radiopharmaceuticals for oncology and therapies for rare diseases.	United States of America	MNPR
Monte Rosa Therapeutics, Inc. Develops molecular glue degraders to target undruggable proteins in cancer and immune diseases.	United States of America	GLUE